Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation
Introduction Androgenetic alopecia is a stressful condition for males. Minoxidil 2% and 5% have been FDA approved for treatment of this condition. In literature, all studies have compared minoxidil 5% with 2%. Although other concentrations (2% to 12.5%) are available nowadays, we believe our study i...
Main Authors: | Soheir Ghonemy, Abeer Alarawi, Hagar Bessar |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-02-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2019.1654070 |
Similar Items
-
Minoxidil: a comprehensive review
by: A. K. Gupta, et al.
Published: (2022-05-01) -
New Target for Minoxidil in the Treatment of Androgenetic Alopecia
by: Shen Y, et al.
Published: (2023-08-01) -
Prolonged hypotension induced by ingesting a topical minoxidil solution: analysis of minoxidil and its metabolites
by: Satoshi Kikuchi, et al.
Published: (2016-10-01) -
Topical Minoxidil-Loaded Nanotechnology Strategies for Alopecia
by: Ana Cláudia Santos, et al.
Published: (2020-03-01) -
Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia
by: Zari Shadi
Published: (2023-04-01)